ALL) + (Ph Philadelphia-positive acute lymphoblastic leukemia + outcome in MRD Early molecular response to posttransplantation imatinib determines

[1]  T. Lipp,et al.  Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. , 2004, Blood.

[2]  M. Lübbert,et al.  Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) , 2003, Leukemia.

[3]  H. Kantarjian,et al.  The biology and therapy of adult acute lymphoblastic leukemia , 2003, Cancer.

[4]  H. Gschaidmeier,et al.  Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment , 2003, Leukemia.

[5]  W. Hofmann,et al.  Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. , 2003, Blood.

[6]  I. Avivi,et al.  Bone marrow transplant in Ph+ ALL patients , 2003, Bone Marrow Transplantation.

[7]  Yoo-Jin Kim,et al.  Risk factors for adults with Philadelphia‐chromosome‐positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real‐time quantitative reverse‐transcription polymerase chain reaction , 2003, British journal of haematology.

[8]  M. Baccarani,et al.  Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190BCR-ABL-positive acute lymphoblastic leukemia , 2002, Leukemia.

[9]  J. Bourhis,et al.  Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. , 2002, Blood.

[10]  D. Grimwade.  The significance of minimal residual disease in patients with t(15;17). , 2002, Best practice & research. Clinical haematology.

[11]  S. de Vos,et al.  Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. , 2002, Blood.

[12]  C. Peschel,et al.  BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study , 2002, The Lancet.

[13]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[14]  B. Löwenberg,et al.  Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. , 2001, Blood.

[15]  J. Radich.  Philadelphia chromosome-positive acute lymphocytic leukemia. , 2001, Hematology/oncology clinics of North America.

[16]  J. Gajewski,et al.  Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults. , 2001, Hematology/oncology clinics of North America.

[17]  T. Lipp,et al.  Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). , 2000, Hematology/oncology clinics of North America.

[18]  D. Hoelzer,et al.  Recent approaches in acute lymphoblastic leukemia in adults. , 2000, Reviews in clinical and experimental hematology.

[19]  M. Amylon,et al.  Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission , 1999, Leukemia.

[20]  E. Macintyre,et al.  Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease , 1999, Leukemia.

[21]  Z. Estrov,et al.  Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. , 1998, Blood.

[22]  J. Radich,et al.  Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. , 1997, Blood.

[23]  C. Preudhomme,et al.  Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL) , 1997, Leukemia.

[24]  S. Singhal,et al.  Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. , 1996, Bone marrow transplantation.

[25]  N. Chao,et al.  Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia [letter] , 1995 .

[26]  A. Zander,et al.  Infusion of tumor-contaminated bone marrow for autologous rescue after high-dose therapy leading to long-term remission in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia. , 1995, Bone marrow transplantation.

[27]  K. Laczika,et al.  PCR‐monitoring of minimal residual leukaemia after conventional chemotherapy and bone marrow transplantation in BCR‐ABL‐positive acute lymphoblastic leukaemia , 1995, British journal of haematology.

[28]  F. Mandelli,et al.  Adult Philadelphia-chromosome-positive acute lymphoblastic leukemia: experience of treatments during a ten-year period. , 1994, Leukemia.

[29]  F. Mandelli,et al.  Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long- term remission , 1993 .

[30]  C. Gisselbrecht,et al.  Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Horowitz,et al.  Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. , 1992, Blood.

[32]  M. Tanimoto,et al.  Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation. , 1992, Blood.

[33]  S. Smith,et al.  Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[34]  H. Gschaidmeier,et al.  Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). , 2003, Blood.

[35]  Sante Tura,et al.  A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.

[36]  R. Storb,et al.  Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.